MesenFlow
@MesenFlow
Followers
8
Following
20
Media
3
Statuses
13
Translational Solutions
The Eclosion Foundation, Chemin des Aulx 14, Plan-les-Ouates, CH1205 Geneva, Switzerland
Joined March 2016
Translational medicine in action, and validation for the MesenFlow strategy. Mesenchymal factors regulate human CD16+ monocyte function in chronic inflammation and cancer.
Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours.
0
0
1
MesenFlow Technologies is proud to be part of a study on circadian rhythms in leukocyte trafficking, published in @ImmunityCP. What a fantastic way to end the year. We wish our friends and colleagues a Happy New Year for 2019!.
0
0
1
Commentary on the publication in Nature Comms, with the founders of MesenFlow Technologies. Applying powerful and deliverable translational technologies to cancer therapy.
sciencedaily.com
For a tumour to grow, it must develop blood vessels that supply nutrients and oxygen. Preventing tumor vascularization is therefore an interesting anti-tumor therapy that has been explored over the...
0
0
0
Valdiating a translational approach in the treatment of cancer & chronic inflammation. A radio interview with author Adama Sidibe about a recent publication in Nature Comms. Further validation of the MesenFlow strategy (In French). via @RadioTeleSuisse.
0
0
0
RT @NatureComms: Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours..
0
6
0
0
0
1
Setting up our stand. MesenFlow Technologies is at the ESM-EVBO 2017 conference in Geneva. Looking forward to seeing you there!
0
0
0
MesenFlow will be at the ESM-EVBO 2017, May 29-June 1st 2017, Geneva, Switzerland
0
0
0
